Selected Publications

2024

Journal Articles- Refereed

M Vu, K Degeling, GL Ryland, O Hofmann, AP Ng, D Westerman, MJ Ijzerman. Economic Impact of Whole Genome Sequencing and Whole Transcriptome Sequencing Versus Routine Diagnostic Molecular Testing to Stratify Patients with B-Cell Acute Lymphoblastic Leukemia. The Journal of Molecular Diagnostics 26 (8), 673-684

M Vu, K Degeling, D Westerman, MJ Ijzerman. Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients. Journal of Cancer Policy, 100501

K Degeling, YH To, K Trapani, S Athan, P Gibbs, MJ IJzerman, F Franchini. Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia. Value in Health 2024/7/6

G Chazan, F Franchini, R Shah, M Alexander, A John, M IJzerman, ...Real World Treatment and Outcomes in ALK-rearranged Non-small Cell Lung Cancer; Results from a Large US-based Database. JTO Clinical and Research Reports, 100662

HA Khorshidi, D Marshall, I Goranitis, B Schroeder, M IJzerman. System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model. Expert Review of Pharmacoeconomics & Outcomes Research 24 (1), 37-47

M Vu, K Degeling, ER Thompson, P Blombery, D Westerman, M IJzerman. Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia. Applied health economics and health policy 22 (1), 107-122

2023

Journal Articles- Refereed

JA Soon, YH To, M Alexander, K Trapani, PA Ascierto, S Athan, MP Brown, ...  F Franchini, M IJzerman. A tailored approach to horizon scanning for cancer medicines. Journal of Cancer Policy 38, 100441

JA Soon, F Franchini, M Ijzerman, GA McArthur. The role of systemic therapies in current and emerging opportunities for de-intensification in melanoma: a scoping review protocol. medRxiv, 2023.11. 21.23298799

P Gillett, RK Mahar, NR Tran, M Rosenthal, M IJzerman. Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value. Cost Effectiveness and Resource Allocation 21 (1), 87

F Franchini, V Fedyashov, MJ IJzerman, K Degeling. Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach. Frontiers in Pharmacology 14, 1255021

A Drosdowsky, KE Lamb, A Karahalios, RJ Bergin, K Milley, L Boyd, MJ IJzerman, JD Emery. The effect of time before diagnosis and treatment on colorectal cancer outcomes: systematic review and dose–response meta-analysis. British journal of cancer 129 (6), 993-1006

M Fagery, HA Khorshidi, SQ Wong, M Vu, M IJzerman. Health economic evidence and modeling challenges for liquid biopsy assays in cancer management: a systematic literature review. PharmacoEconomics 41 (10), 1229-1248

A Drosdowsky, KE Lamb, RJ Bergin, L Boyd, K Milley, MJ IJzerman, ... A systematic review of methodological considerations in time to diagnosis and treatment in colorectal cancer research. Cancer epidemiology 83, 102323

S O’Haire, F Franchini, YJ Kang, J Steinberg, K Canfell, J Desai, S Fox, ... M IJzerman. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours. Scientific reports 13 (1), 4116

A Pereira-Salgado, A Anton, F Franchini, RK Mahar, EM Kwan, S Wong, ... M IJzerman. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matters?. Expert Review of Pharmacoeconomics & Outcomes Research 23 (2), 231-239

2022

Journal Articles- Refereed

YH To, P Gibbs, J Tie, M IJzerman, K Degeling. Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. Cost Effectiveness and Resource Allocation 21 (1), 11

YJ Kang, S O’Haire, F Franchini, M IJzerman, J Zalcberg, F Macrae, ... A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. Scientific reports 12 (1), 20495

S O’Haire, K Degeling, F Franchini, B Tran, SJ Luen, C Gaff, K Smith, ... MJ IJzerman. Comparing survival outcomes for advanced cancer patients who received complex genomic profiling using a synthetic control arm. Targeted Oncology 17 (5), 539-548

M Vu, K Degeling, ER Thompson, P Blombery, D Westerman, MJ IJzerman. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. European Journal of Haematology 108 (6), 469-485

J Zhang, MJ IJzerman, J Oberoi, N Karnchanachari, RJ Bergin, F Franchini, ... Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. Lung Cancer 166, 27-39

J Zhang, P Basu, JD Emery, MJ IJzerman, F Bray. Lung cancer statistics in the United States: a reflection on the impact of cancer control. Annals of Cancer Epidemiology 6

K Degeling, MJ IJzerman, CGM Groothuis-Oudshoorn, MD Franken, ... Comparing modeling approaches for discrete event simulations with competing risks based on censored individual patient data: a simulation study and illustration in colorectal cancer. Value in health 25 (1), 104-115

2021

Journal Articles- Refereed

K Degeling, NM Corcoran, A Pereira-Salgado, AA Hamid, S Siva, M IJzerman. Lifetime health and economic outcomes of active surveillance, radical prostatectomy, and radiotherapy for favorable-risk localized prostate cancer. Value in Health 24 (12), 1737-1745

RK Mahar, MB McGuinness, B Chakraborty, JB Carlin, MJ IJzerman, ... A scoping review of studies using observational data to optimise dynamic treatment regimens. BMC medical research methodology 21, 1-13

G Chazan, F Franchini, M Alexander, S Banerjee, L Mileshkin, P Blinman, ... M IJzerman, BJ Solomon. Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. ESMO open 6 (5), 100224

YH To, K Degeling, S Kosmider, R Wong, M Lee, C Dunn, G Gard, A Jalali, ... M IJzerman, P Gibbs, J Tie. Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer. Pharmacoeconomics 39 (8), 953-964

A Pereira-Salgado, EM Kwan, B Tran, P Gibbs, J De Bono, M IJzerman. Systematic review of efficacy and health economic implications of real-world treatment sequencing in prostate cancer: where do the newer agents enzalutamide and abiraterone fit in?. European urology focus 7 (4), 752-763

K Degeling, A Pereira-Salgado, NM Corcoran, PC Boutros, P Kuhn, ... MJ IJzerman. Health economic evidence for liquid-and tissue-based molecular tests that inform decisions on prostate biopsies and treatment of localised prostate cancer: a systematic review. European Urology Open Science 27, 77-87

M Vu, K Degeling, M Martyn, E Lynch, B Chong, C Gaff, MJ IJzerman. Evaluating the resource implications of different service delivery models for offering additional genomic findings. Genetics in Medicine 23 (4), 606-613

J Zhang, J Li, S Xiong, Q He, RJ Bergin, JD Emery, MJ IJzerman, ... Global burden of lung cancer: implications from current evidence. Annals of Cancer Epidemiology 5

H Koffijberg, K Degeling, MJ IJzerman, VMH Coupé, MJE Greuter. Using metamodeling to identify the optimal strategy for colorectal cancer screening. Value in health 24 (2), 206-215

MJ IJzerman, J de Boer, A Azad, K Degeling, J Geoghegan, C Hewitt, ... . Towards routine implementation of liquid biopsies in cancer management: it is always too early, until suddenly it is too late. Diagnostics 11 (1), 103, 2021

K Degeling, NN Baxter, J Emery, MA Jenkins, F Franchini … M IJzerman. An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic. Asia‐Pacific Journal of Clinical Oncology, 2021

2020

Journal Articles- Refereed

W Cui, F Franchini, M Alexander, A Officer, HL Wong, M IJzerman, J Desai, .... Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer 146, 310-317

K Degeling, HL Wong, H Koffijberg, A Jalali, J Shapiro, S Kosmider, ... M IJzerman. Simulating progression-free and overall survival for first-line doublet chemotherapy with or without bevacizumab in metastatic colorectal cancer patients based on real-world … Pharmacoeconomics 38 (11), 1263-1275

K Degeling, MJ IJzerman, MS Lavieri, M Strong, H Koffijberg. Introduction to metamodeling for reducing computational burden of advanced analyses with health economic models: a structured overview of metamodeling methods in a 6-step Application Process. Medical Decision Making 40 (3), 348-363

Maarten J IJzerman, Freek Anne van Delft, Hendrik Koffijberg, Valesca P Retel, Michel van den Heuvel. The validity and predictive value of blood-based biomarkers in prediction of response in the treatment of non-small cell lung cancer: A systematic review. Cancers 2020, 12(5), 1120.

E Faulkner, AP Holtorf, CY Liu, H Lin, E Biltaj, D Brixner… M J IJzerman, K Payne. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group - Value in Health, 2020.

G Chazan, F Franchini, M Alexander, S Banerjee… M J IJzerman, B Solomon. Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO open, 2020.

2019

Journal Articles- Refereed

2018

Journal Articles- Refereed

Degeling K, Koffijberg H, Franken MD, Koopman M, IJzerman MJ. Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer. Med Decis Making. 4 ed. 2018 Dec 27;39(1):57–73.

Broekhuizen H, Groothuis-Oudshoorn CGM, Vliegenthart R, Groen HJM, IJzerman MJ. Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population. Value Health. 2018 Nov;21(11):1269–77.

Degeling K, Franken MD, May AM, van Oijen MGH, Koopman M, Punt CJA, IJzerman MJ et al. Matching the model with the evidence_ comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer Epidemiol. Elsevier; 2018 Oct 12;57:60–7.

Heuvelmans MA, Vonder M, Rook M, Groen HJM, de Bock GH, Xie X, et al. Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography: Current Evidence and Technical Considerations. J Thorac Imaging. 2018 Dec 13;:1.

de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, et al. EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget. 2018 Nov 2;9(86):35705–16.

Berghuis AMS, Koffijberg H, Terstappen LWMM, Sleijfer S, IJzerman MJ. Evidence on the cost of breast cancer drugs is required for rational decision making. Ecancermedicalscience. 2018;12:825.

IJzerman MJ, Berghuis AMS, de Bono JS, Terstappen LWMM. Health economic impact of liquid biopsies in cancer management. Expert Rev Pharmacoecon Outcomes Res. 2018 Aug 7;28(1):1–7.

Witteveen A, Nane GF, Vliegen IMH, Siesling S, IJzerman MJ. Comparison of Logistic Regression and Bayesian Networks for Risk Prediction of Breast Cancer Recurrence. Medical Decision Making. 2018 Oct; 38(7):822-833

Witteveen A, Siesling S, Otten JWM, Vliegen IMH, Timmer JB, IJzerman MJ. Risk-based breast cancer follow-up stratified by age. Cancer Med. 2018 Oct; 7(10):5291-5298

2017

Journal Articles- Refereed

Berghuis AMS, Koffijberg H, Prakash J, Terstappen LWMM, IJzerman MJ. Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility. Int J Mol Sci. Multidisciplinary Digital Publishing Institute; 2017 Feb 9;18(2):363.

Brinkhof S, Groen HJM, Siesling SS, IJzerman MJ. Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences. PLoS ONE. 2017 Dec 7;12(12):e0189251–7.

Broekhuizen H, Groothuis-Oudshoorn CGM, Vliegenthart R, Groen H, IJzerman MJ. Public Preferences for Lung Cancer Screening Policies. Value Health. 2017 Aug;20(7):961–8.

Crown W, Buyukkaramikli N, Thokala P, Morton A, Sir MY, Marshall DA, IJzerman MJ et al. Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value Health. 2017 Mar;20(3):310–9.

Degeling K, IJzerman MJ, Koopman M, Koffijberg H. Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. BMC Med Res Methodol; 2017 Dec 15;17(1):170–12.

Degeling K, Koffijberg H, IJzerman MJ. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models. Expert Rev Pharmacoecon Outcomes Res. Taylor & Francis; 2017 Feb;17(1):17–25.

Degeling K, Schivo S, Mehra N, Koffijberg H, Langerak R, de Bono JS, IJzerman MJ. Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. Value in Health. 2017 Jul;in press(10):1411–9.

Mewes JC, Steuten LMG, IJzerman MJ, van Harten WH. A systematic approach for assessing, in the absence of full evidence, whether multicomponent interventions can be more cost-effective than single component interventions. Int J Technol Assess Health Care. 2017 Sep 11;:1–10.

Mewes JC, Steuten LMG, IJsbrandy C, IJzerman MJ, van Harten WH. Value of Implementation of Strategies to Increase the Adherence of Health Professionals and Cancer Survivors to Guideline-Based Physical Exercise. Value in Health. 2017 Jun.

Otten JWM, Witteveen A, Vliegen IMH, Siesling S, Timmer JB, IJzerman MJ. Stratified Breast Cancer Follow-Up Using a Partially Observable MDP. In: Markov Decision Processes in Practice. Cham: Springer, Cham; 2017. pp. 223–44. (International Series in Operations Research & Management Science; vol. 248).

van Harten W, IJzerman MJ. Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments. Ecancermedicalscience. 2017;11:ed71.

2016

Journal Articles- Refereed

Malone DC, Berg NS, Claxton K, Garrison LP, IJZERMAN M, Marsh K, et al. International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. J Clin Oncol. American Society of Clinical Oncology; 2016 Aug 20;34(24):2936–7.

2015

Journal Articles- Refereed

Mewes JC, Steuten LMG, Groeneveld IF, de Boer AGEM, Frings-Dresen MHW, IJZERMAN MJ, et al. Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries. BMC Cancer. 2015 Nov 12;15(1):899.